Testosterone Therapy Can Be Initiated in Patients with Elevated Liver Enzymes, But the Formulation Matters Critically
Non-oral testosterone formulations (intramuscular injections, transdermal gels/patches) can be safely initiated in patients with elevated liver enzymes, as these preparations do not cause hepatotoxicity and do not require routine liver function monitoring. However, oral testosterone preparations (except testosterone undecanoate, which is unavailable in the U.S.) are absolutely contraindicated due to severe hepatotoxic effects including benign and malignant liver tumors 1.
Key Decision Algorithm
Step 1: Determine the Cause of Elevated Liver Enzymes
Before initiating therapy, identify whether the patient has:
- Metabolic dysfunction-associated steatotic liver disease (MASLD): Testosterone may actually be beneficial here
- Cirrhosis: Testosterone can still be used and may improve outcomes
- Active hepatitis or acute liver injury: Requires more caution but not an absolute contraindication for non-oral formulations
Step 2: Select the Appropriate Formulation
- Safe options: Intramuscular testosterone (enanthate, cypionate, undecanoate), transdermal gels, transdermal patches 1
- Absolutely avoid: Oral 17-α alkyl-androgens (associated with hepatic adenomas, hepatocellular carcinoma, and peliosis hepatis) 2
Step 3: Baseline Assessment
Check these parameters before starting:
- Hematocrit (baseline)
- PSA and digital rectal exam (if age-appropriate)
- Confirm hypogonadism with total testosterone <12 nmol/L or free testosterone <230 pmol/L
- Document baseline liver enzymes for comparison
Evidence Supporting Safety in Liver Disease
The evidence actually suggests testosterone therapy may improve liver function in certain contexts:
In MASLD patients: A 2025 meta-analysis demonstrated that testosterone treatment reduces liver steatosis, improves liver enzymes, and may even regress liver fibrosis 3. The prevalence of biochemical liver damage during testosterone therapy was only 1% 4.
In cirrhotic patients: Multiple studies show testosterone therapy is safe and beneficial:
- A 2016 randomized controlled trial in 101 men with cirrhosis showed testosterone safely increased muscle mass without increased adverse events 5
- A 2011 study using testosterone gel in cirrhotic patients found no significant adverse effects on liver function 6
- A 2025 emulated trial in Medicare patients with cirrhosis showed testosterone reduced mortality (sHR 0.92) and decompensation events 7
- An 8-year prospective study showed improved liver function indices including decreased bilirubin, triglycerides, and gamma-glutamyl-transferase 8
Monitoring Protocol
Once initiated on non-oral testosterone 9:
- 3-6 months: Check testosterone levels, hematocrit, and liver enzymes
- 12 months: Repeat testosterone, hematocrit, and liver enzymes
- Annually thereafter: Continue monitoring
- No routine liver function monitoring is necessary for intramuscular or transdermal preparations 1
Critical Caveats
Stop therapy if 2:
- Hematocrit exceeds 54% (evaluate for hypoxia/sleep apnea before restarting at lower dose)
- Development of hepatic adenomas or carcinoma (rare, primarily with oral formulations)
- Pre-existing cardiac, renal, or hepatic disease with new-onset edema or congestive heart failure
The hepatotoxicity concern is formulation-specific: The warnings about liver damage in FDA labeling 2 refer primarily to oral 17-α alkyl-androgens and prolonged high-dose use. Intramuscular and transdermal preparations have an entirely different safety profile and do not share this hepatotoxic risk 1.
Elevated liver enzymes alone are not a contraindication to testosterone therapy when using appropriate formulations. In fact, testosterone may improve liver function in patients with MASLD or cirrhosis, potentially reducing cardiovascular mortality and improving quality of life through increased muscle mass, reduced sarcopenia, and improved metabolic parameters 8, 7.